Please visit our MS learning channel on YouTube, which provides hundreds of MS related topics from many of our video recorded education programs and archived here: -- Be empowered with MS views and news. Opt-in with us:

~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Tuesday, November 4, 2014

Cognitive Decline Tracked in Multiple Sclerosis in Longitudinal Study

By Rachel Lutz | November 03, 2014

    Cognitive abilities declined during a longitudinal study of multiple sclerosis (MS) patients, according to research published by the Kessler Foundation and the Cleveland Clinic. The study is one of the longest longitudinal studies of cognition in MS.  

 The researchers wanted to explore and track the cognitive impairment among 22 patients enrolled an ongoing phase 3 trial of intramuscular interferon beta-1a. The participants underwent a longitudinal investigation which compared neuropsychological test performances at baseline and at the 18-year follow up. The patients were enrolled in the original Avonex study conducted in the early 1990s. - 

“While cognitive impairment is known to affect 40 to 65% of individuals with MS, few studies have followed the pattern of cognitive decline over time, which is important for understanding long-term care and outcomes associated with MS,” author Lauren B Strober, PhD senior research scientist at Kessler Foundation, said in a press release. “Our study was based on a unique sample of 22 patients who underwent neuropsychological testing at entry into the original phase 3 clinical trial of intramuscular interferon beta-1a, and again at 18-year follow up.”  

 Declines were observed in the MS patients in areas such as information processing speed, simple and complex auditory attention, episodic learning and memory, and visual constructions. Nearly half of the patients (41 percent) were found to be cognitively impaired at baseline. At the 18-year mark, 13 patients (59 percent) were found to be cognitively compared, when evaluated by the researchers. Both the unimpaired and impaired groups of patients appeared to experience cognitive decline using these measures. One measurement scale, the Symbol Digit Modalities Test showed a group × time interaction. The researchers determined this scale displayed a steeper decline in the unimpaired than the impaired group compared to baseline measurements. -

 See more at:

For MS Views and News - OPT-IN here

No comments: